Abstract
We assessed the relative importance of two serine residues located near the top of transmembrane helix 5 of the human 5-HT2A receptor, comparing the wild type with S5.43(239)A or S5.46(242)A mutations. Using the ergoline lysergic acid diethylamide (LSD), and a series of substituted tryptamine and phenethylamine 5-HT2A receptor agonists, we found that Ser5.43(239) is more critical for agonist binding and function than Ser5.46(242). Ser5.43(239) seems to engage oxygen substituents at either the 4- or 5-position of tryptamine ligands and the 5-position of phenylalkylamine ligands. Even when a direct binding interaction cannot occur, our data suggest that Ser5.43(239) is still important for receptor activation. Polar ring-substituted tryptamine ligands also seem to engage Ser5.46(242), but tryptamines lacking such a substituent may adopt an alternate binding orientation that does not engage this residue. Our results are consistent with the role of Ser5.43(239) as a hydrogen bond donor, whereas Ser5.46(242) seems to serve as a hydrogen bond acceptor. These results are consistent with the functional topography and utility of our in silico-activated homology model of the h5-HT2A receptor. In addition, being more distal from the absolutely conserved Pro5.50, a strong interaction with Ser5.43(239) may be more effective in straightening the kink in helix 5, a feature that is possibly common to all type A GPCRs that have polar residues at position 5.43.
Footnotes
-
This research was supported by National Institute on Drug Abuse grant DA02189, a grant from the Heffter Research Institute, and the work was conducted in a facility constructed with support from Research Facilities Improvement Program grant C06–14499 from the National Center for Research Resources of the National Institutes of Health.
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.107.039255.
-
ABBREVIATIONS: 1-iPr-5-MeO-T, 1-isopropyl-5-methoxytryptamine; 1-Me-5-HT, 1-methyl-5-hydroxytryptamine (1-methylserotonin); 2CH, 2,5-dimethoxyphenethylamine; 2CI, 2,5-dimethoxy-4-iodophenethylamine; 2-Et-DOM, 2-ethyl-5-methoxy-4-methylphenyl-isopropylamine; 5-Et-DOM, 5-ethyl-2-methoxy-4-methylphenylisopropylamine; 5-H-DOM, 2-methoxy-4-methylphenylisopropylamine; 5-HT, 5-hydroxtryptamine (serotonin); 5-Me-T, 5-methyltryptamine; 5-MeO-DMT, 5-methoxy-N,N-dimethyltryptamine; 5-MeO-T, 5-methoxytryptamine; DMT, N,N-dimethyltryptamine; DOH, 2,5-dimethoxyphenyl-isopropylamine; DOI, 4-iodo-2,5-dimethoxyphenylisopropylamine; DOM, 2,5-dimethoxy-4-methylphenylisopropylamine; PI, phosphoinositide; TM, transmembrane; GPCR, G protein-coupled receptor; LSD, lysergic acid diethylamide; ANOVA, analysis of variance; WT, wild type.
- Received June 22, 2007.
- Accepted August 22, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|